Document:

Exhibit 10.58

 

Work Order # 01

 

This Work Order #01 ("Work Order")
dated May 16, 2014 ("Effective Date") is entered into by and between Aethlon Medical Inc. ("Sponsor")
and Total Renal Research, Inc., d/b/a DaVita Clinical Research ("DCR"). Sponsor and DCR shall each be hereinafter
referred to as a "Party" and collectively as the "Parties".

 

Parties, this Work Order is entered into
pursuant to the Master Services Agreement by and between the Parties dated February 14, 2014, (the "Agreement"), which
is incorporated by reference herein.

 

Unless otherwise defined herein all capitalized
terms shall have the same meaning as in the Agreement.

 

The Parties hereby agree as follows:

 

1.Services. DCR shall conduct
the Services as outlined in Attachment 1 attached hereto, involving the Study Device entitled "A Clinical Safety Study
of the Aethlon HemopurifierrE0 in Chronic ESRD Patients with HCV Infection" (the "Study"), bearing protocol
ID# AEMD-IDE-2013 v1.09, dated March 31, 2014, together with any of its subsequent revisions (the "Protocol"), the provisions
of which are attached hereto and incorporated herein by reference. The Protocol may be revised only at the direction of and with
the prior written approval of the Sponsor, subject to subsequent approval by the Institutional Review Board ("IRB").

 

2.Deliverables. The Deliverables
required to be delivered pursuant to this Work Order shall include: Intentionally omitted.

 

3.Acceptance Criteria. The
Acceptance Criteria for any such Deliverables shall be as follows: Intentionally omitted.

 

4.Work Order Term. The term
of this Work Order shall commence as of the Effective Date and shall continue until the Services are completed, unless otherwise
agreed to by the parties ("Work Order Term"). If the Agreement expires during the Work Order Term then the Parties specifically
agree that this Work Order shall survive and the terms of the Agreement shall continue to apply to this Work Order during the
Work Order Term.

 

5.Budget and Payment Schedule.
Sponsor shall make payments to DCR for Fees and Expenses in accordance with the terms of the Agreement and the Payment Schedule
attached hereto as Attachment 2.

 

6.Subcontractor. Through execution
of this Work Order and the applicable Clinical Trial Agreement or Investigator Agreement (form of which is attached hereto as
Attachment 4), Sponsor approves DCR's use of third party consulting physicians (each an "Investigator")
at certain sites, including a network of dialysis centers owned and operated by a DCR affiliate (each a "Site").

 

 

    	1

    	 

    

 

7. Invoicing and Payment Detail.

 

A.Invoices to Sponsor shall be sent to Sponsor via e-mail
at:

 

Name: Jim Frakes

e-mail: jfrakes@aethlonmedical.com

 

B.Payment to DCR shall be made electronically as follows:

 

Bank Name: Wells Fargo

Bank ABA/Routing #: XXXXXXX*

Account Name: Total Renal Research, Inc.

Account Number: XXXXXXX*

 

C.All payments shall reference project number: 13-M-0249-00

 

7.Conflict. To the extent that
the terms of the attachments hereto conflict with either the terms of the Agreement or this Work Order such terms shall be controlled
by the Agreement or Work Order, as applicable.

 

8.Delay of Study. In the event
of a Sponsor derived postponement of Hemopurifiere treatment (including but not limited to: Device shipment, Device usability,
Study approval by governing boards), or a Sponsor-derived postponement or cancellation of the Study, Sponsor and DCR will negotiate
the cost consequences with the intent that DCR shall be paid for activities and services earned (including any non-cancellable
items) for their participation in the Study.

 

The remainder of this page intentionally
left blank.

 

Signatures to follow.

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

 

    	2

    	 

    

 

 

IN WITNESS WHEREOF,
the Parties have caused this Work Order to be executed by their duly authorized representatives as of the Effective Date.

 

 

 

 

 

 

 

    	3

    	 

    

 

ATTACHMENT 1

Services

 

The following Services will be provided
by DCR to Sponsor with respect to the Study as described in the Sponsor Protocol and in accordance with the terms of the Agreement:

 

1. Site Management and Clinical Study Conduct

 

A.DCR will conduct site management
administrative services ("Services") for Study Sites in accordance with the Protocol, attached hereto and incorporated
herein. The Services will include: (i) selection of Sites for the Study including (1) the ability to enroll the desired number
of patients; (2) availability of an appropriate population to meet the inclusion and exclusion criteria; (3) identification of
proposed Investigators for each Site prior to his/her participation in the Study (it being understood that Sponsor reserves the
right to approve or disapprove individual Investigators); and (4) confirming that prospective, replacement and current clinical
investigators are not listed by the FDA as unacceptable to conduct clinical investigation; (ii) the preparation of all Investigational
Review Board (IRB) materials to be submitted to a central IRB and assistance, as needed, to those Sites (if any) using their own
internal IRB; (iii) providing payments to Sites or Investigators, or both, upon and subject to receipt of funds from Sponsor; (iv)
providing or coordinating ongoing onsite orientation and training of all Investigators and their support personnel as needed with
regard to compliance with the Protocol; and (v) providing confirmation of accountability of Investigator performance with regard
to the following aspects of the Study conducted at the respective Sites: (1) the number of subjects screened for the Study; (2)
the number of qualified subjects participating in the Study; and (3) the number of acceptable completed case report forms resulting
from the Study.

 

B.It is understood and agreed that
Services shall not include the clinical activities of any Investigator under an Investigator Agreement or a Clinical Trial Agreement,
as applicable, and that each Investigator is personally responsible for the conduct of the Study in which s/he participates and
shall exercise his/her own independent medical judgment. DCR's responsibilities with respect to Investigators shall be limited
to those responsibilities specifically set forth in this Work Order. DCR will contract with each Investigator for their services
on the Study using an Investigator Agreement or a Clinical Trial Agreement, as applicable, substantially in the form attached hereto
as Attachment 4. DCR shall not perform the Study with an Investigator who has not entered into an Investigator Agreement or for
whom a Clinical Trial Agreement has not been entered into.

 

C.DCR shall perform the Services and
DCR shall inform the Investigator of his/her obligation to perform the Study in compliance with generally accepted standards of
Good Clinical Practice as set forth in Title 21 of the U.S. Code of Federal Regulations, the Protocol, instructions provided by
Sponsor and all applicable local, state and federal laws and regulations governing the performance of clinical investigations
including but not limited to the Federal Food, Drug, and Cosmetic Act, and regulations and guidances of the U.S. Food and Drug
Administration (FDA), the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and all other applicable
medical privacy laws and regulations; and any conditions imposed by the IRB.

 

    	4

    	 

    

 

D.The Study shall commence upon execution
of this Work Order and the applicable Investigator Agreement(s) or the Clinical Trial Agreement(s), as applicable. The Study shall
enroll up to ten (10) patients meeting all Protocol eligibility requirements. Sponsor shall not be obligated to pay any sums for
tests performed on individuals who do not meet all Protocol eligibility criteria for the Study or for additional individuals who
are enrolled in the Study without Sponsor's prior written approval. In the case where DCR enrolls ten (10) subjects, and one or
more subjects discontinues, DCR will contact Aethlon regarding enrollment of additional subjects to meet Aethlon's primary endpoint.
Notwithstanding the foregoing, if Sponsor and DCR agree in writing to increase the number of subjects for the Study, Sponsor shall
pay DCR additional compensation for such additional subjects as may be agreed upon between the parties.

 

E.DCR shall, as part of the Services,
use its best efforts to cause all Investigators to: (i) timely submit to DCR, Sponsor and/or Sponsor's designee, clean and completed
original case report forms for each Study subject as provided in the Protocol; and (ii) provide to DCR (and DCR will then provide
to Sponsor) completed FDA form 1572 and sufficient accurate financial information on FDA forms 3454/3455 to allow Sponsor to submit
complete and accurate certification or disclosure statements as required by 21 C.F.R. Part 54 and promptly update this information
if any relevant changes occur during the course of each Study, and for one year following the completion of the Study.

 

F.At the completion of the Services
for the Study by DCR or upon the earlier termination of the Agreement or this Work Order, all materials, information and all other
data owned by Sponsor with respect to the transactions covered by this Agreement, regardless of the method of storage or retrieval,
shall be delivered to Sponsor in such form as is then currently in the possession of DCR, or in such data media formats as are
set forth in the Protocol. Sponsor shall pay the costs of delivery of such materials, information and other data from DCR to Sponsor.
Alternatively, at Sponsor's written request, such materials and data may be retained by DCR for Sponsor for an agreed-upon time
period, or disposed of pursuant to the written directions of Sponsor. If materials are so retained, Sponsor shall pay a to-be-determined
fee for storage by DCR of records and materials after completion or termination of the Services. DCR, however, reserves the right
to retain, at its own cost and subject to the confidentiality provisions herein, copies of all materials that may be needed to
satisfy regulatory requirements or to resolve disputes regarding the Study.

 

G.During the term of this Agreement,
DCR will permit Sponsor's representatives (unless such representatives are competitors of DaVita HealthCare Partners Inc.) to examine
or audit the work performed hereunder upon reasonable advance notice during regular business hours to determine that the Study
is being conducted in accordance with the Protocol. Any access to any Study Sites granted by DCR to Sponsor's representatives hereunder
shall be limited to purposes related to the Study.

 

 

    	5

    	 

    

 

H.If Sponsor is providing Device for purposes of the Study,
then neither Investigators nor DCR shall bill third party payers for such Device. Neither Investigators nor DCR shall bill third
party payers for Study related items and services except as permitted by applicable payer coverage rules.

 

 

 

 

 

 

 

 

 

 

    	6

    	 

    

 

ATTACHMENT 2

Payment Schedule, Payment Terms and
Budget

 

1.0Payment Terms

 

1.1The Budget set forth herein is based
on the specific charges applicable for the Services. The Budget will change to reflect modifications in the scope of Services.
Applicable DCR service fees, as related to enrollment, will also change with said modifications. Sponsor shall pay to DCR the amounts
specified in the Budget in accordance with the payment schedule outlined in the Payment Schedule. The parties acknowledge and agree
that the terms and conditions of the Budget are confidential and shall be treated as Confidential Information in accordance with
the provisions of Section

 

11 of the Agreement.Payments will be
reconciled as a part of the financial reconciliation at the time of the final payment set forth in the Payment Schedule.

 

1.2Sponsor will reimburse DCR monthly
on a completed-visit-per-Subject basis in accordance with the Budget herein. In the event of an amendment to the Protocol that
modifies the Services to be provided under this Work Order, Sponsor and DCR shall negotiate in good faith any modification to the
payments hereunder in an amount equal to the Services added or eliminated by the Protocol amendment and agree to this change in
writing (email is sufficient). Furthermore, pricing for both Study Site and DCR Services may be subject to change in accordance
with any change in Study scope. Completed-visit-per-Subject payment due, including any screen failure payments that may be payable
under the terms of this Work Order, will be made based upon prior month enrollment data as entered into the DCR Clinical Trial
Management System (CTMS) and on submission of an invoice by DCR to this effect. All screen failures will be paid at the screening
rate. DCR shall, verify and reconcile this enrollment data with Sponsor, and appropriate payment adjustments shall be made on the
presentation of an invoice from DCR. Sponsor shall provide proper documentation necessary to complete said reconciliation. DCR
Services will be invoiced to Sponsor in accordance with the progression of the Study.

 

1.3In the event of premature termination of this Work Order
by Sponsor for any reason other than for DCR's breach, Sponsor shall pay DCR for services performed up to and including the date
of termination and expenses incurred up until the date of termination in accordance with the budgeted amounts set forth in the
Budget. Upon receipt of such notice of termination DCR will, and will direct the study Site and Investigator to, take all reasonable
steps to cease conduct of the Study as soon as reasonably possible and to protect the safety, heath, and welfare of the subjects
participating the Study. The parties agree to work collaboratively in the orderly termination of the study, under the direction
of the Sponsor. Sponsor shall pay DCR for the additional services involved in Study termination, according to the amounts set forth
in the Budget for such services and other reasonable, documented Study procedures or expenses.

 

    	7

    	 

    

 

 

1.4 All payments shall be payable in U.S. dollars and made within thirty (30) days of
Sponsor’s receipt of an invoice dealing DCR’s Services under this Work Order or incurrence of pass-through
expenses, and only after full execution of this Work Order. If any portion of any invoice is disputed, then Sponsor shall pay
the undisputed amounts as set forth in the preceding sentence and the Parties shall use good faith efforts to reconcile the
disputed amount as soon as practicable. Sponsor shall pay DCR interest in an amount equal to one percent (1%) per month (or
the maximum lesser amount permitted by law) of all undisputed amounts owing hereunder and not paid within forty-five (45)
days of the date of the invoice.

 

1.5 DCR shall be responsible for making monthly payments to the Site and Investigator upon Site’s
entry of completed study activities into the Clinical Trrial Management System (CTMS).

 

1.6 Terms of the budget shall remain confidential.

 

2.0 Payment Schedule

 

 

Patient compensation for study time and effort will be paid to DCR on a monthly bases with the
concurrent study visit payment. Patients will be compensated for each completed visit by the Study Site. Payment for
patients who are terminated prior to the end of the study will be prorated for actual visits completed.

 

 

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	8

    	 

    

 

2.2DCR Project Management of XXXXXXX* of the total invoiced
patient and site pricing costs will be added to each monthly invoice.

 

2.3All per occurrence fees and pass
through costs payable hereunder shall be paid in full within 30 days of Sponsor's receipt of invoice from DCR.

 

2.4Disposal fee for used Hemopurifier
will be paid by Sponsor to DCR following last patient last visit.

 

2.5The following will be retained for each Site in the Study:-

 

i)Site Close Out Visit

 

iii)Record Storage Fee

 

Which will be paid by Sponsor to DCR promptly
following the occurrence of all of the following events: a) final acceptance by Sponsor of all CRFs b) all data clarifications
issued, and c) upon satisfaction of all other applicable conditions set forth in the Agreement. Sponsor shall make all efforts
to complete these activities in a timely basis. Sponsor shall notify DCR upon each site's official completion of the above conditions.

 

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	9

    	 

    

 

 

 

 

 

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	10

    	 

    

 

 

 

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

 

    	11

    	 

    

 

ATTACHMENT 4

 

Form of Clinical Trial Agreement

 

CLINICAL TRIAL AGREEMENT

 

This Clinical Trial Agreement (Agreement), effective
as of __________________ , 2014, is entered into by and among [NAME OF INSTITUTION] (Institution), Total Renal
Research, Inc., d/b/a DaVita Clinical Research with offices located at 825 South 8th Street, Suite 300, Minneapolis,
MN 55404 (DCR), Aethlon Medical Inc. with offices located at 8910 University Center Lane, Suite 660, San Diego,
CA 92122 (Sponsor) and [NAME OF INVESTIGATOR], M.D. (Investigator).

 

Background  

Sponsor is engaged in research
and development of blood purification medical devices including the conduct of clinical trials involving the use of Hemopurifier®
(Study Device). Institution and the Investigator are engaged in the treatment of patients with chronic early stage renal
disease. Sponsor and DCR have entered into a Master Services Agreement and Work Order pursuant to which DCR will provide site management
services in connection with the Study (as defined below). The clinical study contemplated by this Agreement (the Study) is
of mutual interest and benefit to the Institution, Investigator and Sponsor; and Sponsor Protocol No. ID# AEMD-IDE-2014 entitled
""A Clinical Safety Study of the Aethlon Hemopurifie? in Chronic ESRD Patients with HCV Infection"," dated
May 13, 2013, which shall guide the performance of the Study has been prepared by Sponsor and accepted by the Institution and DCR
(such protocol, together with any of its subsequent amendments, the Protocol).

 

NOW, THEREFORE, in consideration
of the foregoing premises and the covenants contained herein the parties agree as follows:

 

1.SCOPE OF WORK

The Investigator shall carry
out the Study in a professional, competent manner in accordance with the Protocol, the terms of this Agreement and any applicable
Institution policies. Institution shall use its best efforts to ensure that the Investigator shall carry out the Study in accordance
with the Protocol and the terms of this Agreement. The Protocol shall be provided to DCR and the Investigator by Sponsor.

 

2.PERFORMANCE PERIOD AND ENROLLMENT OF SUBJECTS

The Study will commence upon
execution of this Agreement and will continue until completion of the Study as required by the Protocol (including any amendments
thereto), unless this Agreement is terminated earlier pursuant to Section 5 hereof.

 

3.SERIOUS ADVERSE EXPERIENCE REPORTING

If Institution and/or Investigator receives
notice of a Serious Adverse Experience (defined herein) related to the investigational Device, Institution and/or Investigator
shall provide Sponsor with notice within twenty-four (24) hours of learning of the event and provide such additional information
thereafter as reasonably requested by Sponsor. Furthermore, upon Sponsor's reasonable request, Institution and/or Investigator
shall promptly investigate any such Serious Adverse Experience and shall submit follow-up reports of new information in
a timely manner. "Serious Adverse Experience" refers to an experience that has any serious adverse effect on
health or safety or any life-threatening problem caused by, or associated with, a Device, if that effect, problem, or death was
not previously identified in nature, severity, or degree of incidence in the investigational plan or application, or any other
unanticipated serious problem associated with a Device that relates to the rights, safety, or welfare of subjects. Any untoward
event which occurs regardless of its causality, including any side effect, injury, toxicity or sensitivity reaction
during the testing of protocol treatments (whether or not considered Device-related), will be designated as an unanticipated adverse
effect and recorded on the adverse events page of the Case Report Form (CRF).

 

    	12

    	 

    

 

4.PAYMENT

Cost and payment terms are set forth in
Exhibit A of this Agreement and incorporated herein by reference. The parties acknowledge and agree that, as between
DCR, Institution and Investigator, the terms and conditions of Exhibit A are confidential and shall be treated by
DCR, Institution and Investigator as Confidential Information in accordance with the terms and conditions of Section 6.2 of this
Agreement. Without limiting the generality of the foregoing, neither DCR, nor Sponsor, nor Institution, nor Investigator shall
disclose the terms and conditions of Exhibit A without the prior written consent of the others, unless such disclosure
is required by applicable law. Institution represents and warrants that the compensation provided under the terms of this Agreement
shall be consistent with fair market value in arm's length transactions, and has not been determined in any manner with regard
to, or has been given in exchange for, any implicit or explicit agreement to provide favorable procurement decisions with regard
to Sponsor's products, or to the value or volume of any business generated between the parties, and that the services to be performed
under the Agreement do not and will not involve the counseling or promotion of a business arrangement or other activity that violates
any state or federal law.

 

5.TERMINATION

A. This Agreement may be terminated:

		(1)	by DCR or the Institution upon thirty (30) days' prior
                                         written notice;

		(2)	by Sponsor immediately upon written notice;

		(3)	by
                                         either DCR, the Institution or Sponsor immediately if the Investigator is unable to continue
                                         to serve and a successor acceptable to both the Institution and Sponsor is not available;
                                         or

		(4)	by
                                         either DCR, the Institution or Sponsor upon the occurrence of an event qualifying as
                                         a termination event as described in the Protocol.

 

B.
Immediately upon receipt of a notice of termination, the Investigator shall stop enrolling Subjects into the Study and shall cease
conducting procedures on Subjects already enrolled in the Protocol as directed by Sponsor, to the extent medically permissible
and appropriate.

 

C.
In the event that this Agreement is terminated in accordance with Section 5.A, DCR will credit or return to Sponsor any funds
not expended or obligated by the Institution in connection with the Study prior to the effective termination date.

 

D.
Upon the effective date of termination, DCR shall conduct an accounting of expenses chargeable to Sponsor. Sponsor shall
verify the charges presented by DCR and if Sponsor objects to any charge, the parties shall use best efforts to resolve
expeditiously any disagreement. Within thirty (30) days after receipt of adequate documentation or resolution of any dispute,
Sponsor shall make payment to DCR for:

    	13

    	 

    

 

		(1)	all services properly rendered and monies properly expended by the Institution
prior to the date of termination and not yet paid for; and

		(2)	reasonable non-cancelable obligations properly incurred for the Study by
the Institution prior to the effective date of termination.

 

E.
Termination of this Agreement by any party shall not affect the rights and obligations of the parties accrued prior to the effective
date of the termination. The rights and duties under Sections 4, 5, 6, 7, 8, 9, 11, 12, and 13.1-13.9 survive the termination or
expiration of this Agreement.

 

6. CONFIDENTIALITY

6.1 Publicity.

A.Except as is necessary
to comply with applicable laws and regulations or to enforce their respective rights under this Agreement, or to a party's legal
or financial advisors, and except as otherwise agreed to by the parties in writing, the parties shall keep the material terms of
this Agreement confidential. If this Agreement is required to be filed by any party with the Securities and Exchange Commission,
such party shall not file this Agreement with the Securities and Exchange Commission without first notifying the other parties
and seeking confidential treatment for any provisions of this Agreement that any other party believes would disclose trade secrets,
confidential commercial or financial information that would impair the value of the contractual rights represented by this Agreement
or provide detailed commercial and financial information to competitors or third parties.

 

B.No party shall make
(or have made on its behalf) any oral or written release of any statement, information, advertisement or publicity in connection
with this Agreement which uses the other party's name, symbols, or trademarks without the other party's prior written approval.
The obligations of this Section shall survive termination of this Agreement.

 

C.Study results may
not be published or referred to, in whole or in part, by Investigators without the prior expressed written consent of Sponsor.
Sponsor shall include, or cause to be included in any reports, presentations, and publications it makes concerning the Study a
statement that clearly indicates the role of DaVita Healthcare Partners Inc. as a clinical research site for such Study.

 

6.2 Confidentiality.

A. "Confidential
Information" means any and all information, data, and know-how, whether written or oral, technical or non-technical,
including, without limitation, any financial, business, marketing, or operations information, formulas, manufacturing processes,
basic scientific data, prior clinical data, Data (defined herein) or other information provided by or on behalf of a Party or
its Affiliates (the Disclosing Party) to the other Party pursuant to this Agreement (the Receiving Party).
As between DCR, Institution and Investigator, Confidential Information shall also include the terms and conditions of
Exhibit A of this Agreement.

 

    	14

    	 

    

 

 

B. Confidential Information
shall remain the sole and exclusive property of the Disclosing Party. For a period of five (5) years after the receipt of Confidential
Information hereunder, the Receiving Party agrees to hold such Confidential Information in confidence, to only use such Confidential
Information for the purposes of this Agreement and to only disclose such Confidential Information to its employees, agents, Affiliates,
contractors and representatives who are bound by an obligation of confidentiality. Receiving Party also agrees to use the same
degree of care to avoid disclosure of such Confidential Information as the parties employ with respect to their own confidential
information of like importance, but in no event less than a reasonable amount of care;

 

C. Exceptions. Confidential Information shall not include
information that:

 

(i)at the time of disclosure,
or thereafter, has become publicly available, except by breach of this Agreement;

(ii)was in the possession
of the Receiving Party prior to disclosure hereunder as evidenced by competent records;

(iii)was developed
by a Receiving Party independently from and without reference to Confidential Information received hereunder; or

(iv)a Receiving Party
received from a third party without an obligation of confidentiality.

 

D. Compliance with Applicable
Law.Notwithstanding any other terms contained herein, a Receiving Party may disclose Confidential Information received
hereunder to the extent required by applicable law provided that such Receiving Party provides notice to the Disclosing Party as
soon as reasonably practicable under the circumstances and agrees to cooperate in Disclosing Party's efforts to obtain a protective
order or other appropriate remedy. Any information disclosed pursuant to this paragraph shall otherwise remain Confidential Information.

 

E.
Return of Confidential Information. Upon request of a Disclosing Party, a Receiving Party shall return to such Disclosing
Party all Confidential Information received from that Disclosing Party pursuant to this Agreement.

 

F.
Subject Information. If DCR, Institution, Investigator, Sponsor or Sponsor's Designee (as defined below) shall come into
contact with any Study Subject's medical records, each of them shall hold in confidence the identity of such Subject and shall
comply with all applicable law(s) regarding the confidentiality of such subject's records. To the extent that DCR, the Investigators,
or any other person or entity involved in the Study (other than as a subject) is a "covered entity" under the Health
Insurance Portability and Accountability Act of 1996 (HIPAA), DCR warrants that DCR will cause Investigators to
obtain a valid HIPAA Privacy Rule authorization, as prescribed in 45 C.F.R. §164.508(b) from each individual participating
in the Study permitting disclosures from DCR and/or the Investigators to Sponsor and any and all other clinical trial service
providers of the individual's "protected health information" (as defined in HIPAA) as required by and in accordance with the
Study, which such authorization will permit Sponsor's use [and disclosure] of such protected health information for the purposes
of monitoring the accuracy and completeness of the research data, performing clinical and scientific research, and medical product
development.

 

    	15

    	 

    

 

7. PROPRIETARY RIGHTS

A.All information
directly resulting from the Study conducted under this Agreement, including all Data (as defined herein), results, conclusions,
discoveries, inventions, know-how and the like, whether patentable or not (collectively, Inventions) shall be promptly and
fully disclosed by Institution and/or Investigator to Sponsor. Data shall mean all case report forms and other Study data generated
by DCR, Institution or Investigator in the course of conducting the Study and required to be delivered to Sponsor pursuant to the
Protocol.

 

B.Sponsor shall
have the unrestricted right to freely utilize all such Inventions in whatever manner it desires. All Inventions shall be the sole
property of Sponsor excluding the identity of any Study Subject or such Subject's "protected health information" (as
defined in the HIPAA Privacy Rule) unless the Subject has provided authorization or a waiver has been provided. Institution and/or
Investigator shall assist Sponsor, at Sponsor's expense, in the preparation of all documentation necessary to effectuate and perfect
Sponsor's rights in such Inventions.

 

C.The use of the
Study Device by DCR, the Institution or the Investigator for any purpose outside of the Study is prohibited by this Agreement.
While Sponsor in no way condones the use of the Study Device for any purpose outside of the Study, if such work is performed, all
data, results, conclusions, observations, discoveries, inventions, ideas, know-how, procedures, advancements and the like, whether
patentable or not, shall be treated in all respects as Inventions in accordance with this Agreement and shall be the sole property
of Sponsor.

 

D.Neither Sponsor,
DCR, nor the Institution transfers to the other by operation of this Agreement any patent right, copyright right, or other proprietary
right of any party, except as described in this Agreement.

 

8. PUBLICATION

Neither DCR, Institution
nor Investigator shall publish any articles or make any presentations relating to the services, Sponsor Confidential Information
or referring to Data generated pursuant to this Agreement, without the prior written consent of Sponsor.

 

9. CHANGES TO THE PROTOCOL

A.
If generally accepted standards of Good Clinical Practice as set forth in Title 21 of the U.S. Code of Federal Regulations (C.F.R.)
(GCP) relating to the safety of Subjects require a deviation from the Protocol, these standards shall be followed.
Any party who becomes aware of the need for a deviation from the Protocol shall immediately inform the other parties to this Agreement
of the facts causing the deviation as soon as the facts are known to the party. In addition, the Investigator shall promptly inform
the Institution's institutional review board ("IRB") of the deviation.

 

    	16

    	 

    

 

B.
Sponsor may also, from time to time, make changes to the Protocol. Any such changes may not be implemented before approval by
the IRB. If these changes shall affect the cost of the Study, DCR and Sponsor shall agree to the changes in Exhibit A to
reflect the changes in the Study cost and the change shall not be implemented until Sponsor agrees in writing to assume responsibility
for the new costs.

 

10.MATERIALS

Sponsor agrees to provide Study Device
and any reagents that may be required during the course of the Study. Access to any Materials shall be limited to only those persons
who, under the Investigator's direct control, shall be using Materials for the Study. The term "Materials"
shall include the Study Device, reagents and materials derived from Subjects enrolled in the Study, including, but not limited
to, blood, bone marrow, sera, and other biological materials. At no time shall any Materials be used for any purpose other than
as described in the Protocol or transferred to any third party without Sponsor's prior written consent. Upon termination or completion
of the Study, all unused Materials shall be returned to Sponsor or destroyed at Sponsor's sole option; provided, however, that
Institution shall be permitted to retain blood, bone marrow, sera, and other biological materials as needed for record keeping
purposes in accordance with Institution's policies and practices.

 

11.COMPLIANCE WITH LAW AND ACCEPTED PRACTICE

A.The Institution and the
Investigator shall perform the Study in compliance with generally accepted standards of GCP, the Protocol, consistent instructions
provided by Sponsor and all applicable local, state and federal laws governing the performance of clinical investigations including
but not limited to the Federal Food, Drug, and Cosmetic Act, regulations and guidances of the United States Food and Drug Administration
(FDA). The Institution and Investigator shall permit Sponsor and agencies such as the FDA to inspect Study
records including the Subjects' medical records. The subject informed consent form signed by the Subjects shall provide for access
to the Subjects' medical records by Sponsor and by agencies such as the FDA.

 

B.The Investigator will
direct and monitorthe Study in accordance with Section 1. Sponsor shall have the right to (a) monitor and audit the activities
of the Investigator in the conduct of the Study, and (b) monitor and audit the collection of Inventions from the Study.

 

C.Each of the
Institution and Investigator hereby represents and warrants that neither the Institution, the Investigator, nor any of the
Institution's nor Investigator's agents or employees rendering services in connection with the Study, respectively,is
presently:(1) excluded, debarred, suspended or otherwise ineligible to participate in federal health care programs as
defined in 42 U.S.C. Sec. 1320a-7b or from federal procurement or non-procurement activities as defined in Executive Order
12689 (collectively "Ineligible"); or (2) debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C.
Sec. 335 (a), as amended, or any similar state law or regulation (collectively "Debarred") or; (3) convicted of a
criminal offense that falls within the ambit of 42 U.S.C. Sec 1320a-7(a), but has not yet been excluded, debarred, suspended,
or otherwise declared ineligible ("Convicted"). The Institution and Investigator also each represent and warrant
that if any of their respective agents or employees becomes Ineligible, Debarred or Convicted during the Term, they will
notify Sponsor promptly, and in any event no later than five (5) business days after receiving notification of the
Ineligibility, Debarment, or Conviction.

 

    	17

    	 

    

 

D.The arrangements set
out in this Agreement do not take effect and are not intended to take effect as an incentive or reward for a person's past, present
or future willingness to prescribe, administer, recommend (including formulary recommendations), purchase, pay for, reimburse,
authorize, approve or supply any product or service sold or provided by Sponsor or as an incentive to grant an interview for any
sales or marketing purposes.

 

E.The parties shall
not pay or promise to pay, or authorize the payment of any money, or give, promise to give or authorize the giving of anything
of value to any government official, healthcare professional or person affiliated with a healthcare organization to obtain or retain
business or secure improper advantage. Further, the parties represent and warrant that they have not made prior to the Effective
Date any payment, authorization, promise or gift of the sort described in this paragraph.

 

F.The parties shall
comply with the requirements of the U.S. Foreign Corrupt Practices Act and any other applicable anti-corruption national or international
laws and regulations. Further, each party hereby represents, warrants and covenants that they have not, and agrees that it will
not, in connection with the transactions contemplated by this Agreement, make, promise or offer to make any payment or transfer
anything of value: (a) to any foreign government official or to an intermediary for payment to any foreign government officials;
or (b) to any political party. Further, no payments or transfer of value shall be made which have the purpose or effect of public
or commercial bribery, acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining or
retaining business.

 

G.If any governmental
or regulatory authority conducts or gives notice to Institution of its intent to conduct an inspection at Institution's facilities
or take any other regulatory action with respect to the Study, Institution will promptly give Sponsor notice thereof, including
all information pertinent thereto. Sponsor acknowledges that Sponsor may not direct the manner in which Institution fulfills its
obligations to permit inspection by governmental entities. It shall not be a breach of this Agreement for Institution to comply
with the demands and requests of any governmental entity in accordance with Institution's judgment or to fail to inform and consult
with Sponsor before complying with any such demand or request. Except as permitted by this section, neither Institution nor Investigator
shall communicate with the FDA or any other governmental agency concerning the subject matter hereof unless required by law or
requested to do so by Sponsor and, then, only upon prior consultation with Sponsor.

 

H.Neither DCR, Investigator
nor Institution shall bill third party payers for Study related items and services except as permitted by applicable payer coverage
rules.

 

12. INDEMNIFICATION, DISCLAIMER AND INSURANCE

 

    	18

    	 

    

 

A.Subject
to the provisions of Section 12.D, Sponsor will defend, indemnify and hold harmless DCR, Investigator, Institution, and DCR's
and Institution's parent corporations, affiliates, officers, directors, employees, agents, and their successors and assigns (each,
a Indemnified Party) from and against any and all costs (including reasonable attorneys' fees), expenses,
damages and judgments or liabilities (collectively, Losses) arising from or related to any third party claims,
demands, actions or suits, for illness or personal or bodily injury (including death) to a Subject participating in the Study.
The foregoing indemnification action shall not apply in the event and to the extent that (a) such Losses are determined to have
resulted from any Indemnified Party's gross negligence, intentional misconduct or negligence; or (b) Investigator(s) or those
assisting them did not adhere to the terms of the Protocol and to Sponsor's written instructions relative to the use of substances
administered in the Study or failed to employ reasonable care in the conduct of the Study in conformity with the generally accepted
standards of the medical community or violated any applicable laws or regulations in any material respect. For purposes of this
Section 12.A, a violation shall be deemed "material" if it adversely affects the safety, health or welfare of Study
subjects.

 

B.It is understood and agreed that,
Investigators are not employees or agents of DCR and that DCR shall not be required to indemnify Sponsor or its agents or employees
for any claims, suits or damages arising as a result of, or in connection with, the willful misconduct or negligent acts or omissions
of any Investigator. DCR shall, however, cause each Investigator to maintain professional liability insurance with policy limits
of at least $1,000,000 per claim and $3,000,000 annual aggregate.

 

C.In the event a Subject participating
in the Study suffers an illness or injury which the Investigator and Sponsor reasonably determine to be an adverse reaction to
the Sponsor material being tested in the Study or Study procedures required by the Protocol then, subject to the Indemnified Party's
compliance with Section 12.D, Sponsor shall pay all necessary and reasonable medical expenses directly associated with the emergency
medical treatment of such adverse reaction. In the event diagnostic procedures are required to determine the etiology of the patient's
symptoms, Sponsor shall pay the reasonable expense of such diagnostic work-up without regard to the final diagnosis, so long as
Sponsor agrees to the need for the diagnostic work-up, but Sponsor shall not be responsible for expenses connected with the subsequent
treatment of the patient if the work-up establishes that the patient's symptomology is not related to the administration of the
Sponsor material being tested in the Study or Study procedures required by the Protocol. Payments under this Section 12.0 shall
be in addition to any payments specified in Section 12.A.

 

D.To receive the benefit of
indemnification under Section 12.A, the Indemnified Party must promptly notify Sponsor in writing of a claim or suit and
provide reasonable cooperation (at Sponsor's expense) and tender to the Sponsor authority to defend or settle the claim or
suit; provided, however, that Sponsor shall not enter into any settlement of any claim that is based on any admission
of liability by an Indemnified Party without such Indemnified Party's consent. Sponsor has no obligation to indemnify the
Indemnified Party in connection with any settlement made without the Sponsor's written consent. The Indemnified Party has the
right to participate at its own expense in the claim or suit and in selecting its own counsel therefor. The Indemnified Party
shall cooperate with Sponsor, as reasonably requested, at Sponsor's cost and expense.

 

    	19

    	 

    

 

E. EXCEPT FOR BREACH OF CONFIDENTIALITY
OBLIGATIONS UNDER SECTION 6.2 AND EXCEPT AS OTHERWISE PROVIDED IN SECTION 12.A WITH RESPECT TO THIRD PARTY CLAIMS IN NO EVENT SHALL
ANY PARTY BE LIABLE TO THE OTHER FOR PUNITIVE, EXEMPLARY, CONSEQUENTIAL, INCIDENTAL, SPECIAL, OR INDIRECT DAMAGES, INCLUDING LOSS
OF PROFITS, IN TORT OR CONTRACT, AS A RESULT OF THIS AGREEMENT.

 

13. GENERAL PROVISIONS.

13.1 Governing Law. This Agreement
shall be governed and construed in accordance with the laws of Delaware to the exclusion of any choice or conflict of laws rule
or provision that would result in the application of the substantive law of any other jurisdiction.

 

13.2 Amendment and Waiver. No provision
of or right under this Agreement shall be deemed to have been waived by any act or acquiescence on the part of any party, its agents
or employees, but only by an instrument in writing signed by an authorized officer of each party. No waiver by any party of any
breach of this Agreement by any other party shall be effective as to any other breach, whether of the same or any other term or
condition and whether occurring before or after the date of such waiver.

 

13.3 Relationship of the Parties. In
the activities connected with the Study, DCR, Institution and Investigator are, and shall in all respects act as, independent contractors
without the capacity to bind Sponsor or any other party, and DCR, Institution and Investigator also agree that they are not acting
as agents or employees of Sponsor. Notwithstanding anything contained in this Agreement to the contrary, DCR, Institution and Investigator
shall not initiate or participate in any communications with the FDA or any other governmental agency concerning the subject matter
hereof unless required by law or requested to do so by Sponsor and, then, only upon prior consultation with Sponsor.

 

13.4 Assignment. Neither the Institution
nor the Investigator may assign or transfer any of their rights or obligations under this Agreement without the prior written consent
of Sponsor and DCR. Any attempted assignment in violation of the provisions of this Section 13.4 will be void. This Agreement shall
bind and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

 

13.5 Notices. Unless otherwise provided
herein, any notice, report, payment or document to be given by one party to the other shall be sent by registered or certified
mail, postage prepaid, or by overnight courier service. Notices may be sent by facsimile or e-mail, if confirmed by also sending
as described above.

 

13.6 Severability. If any provision(s)
of this Agreement should be illegal or unenforceable in any respect, the legality and enforceability of the remaining provisions
of this Agreement shall not in any way be affected.

 

    	20

    	 

    

 

13.7 Captions; Word Meanings. Captions
of the sections and subsections of this Agreement are for reference purposes only and do not constitute terms or conditions of
this Agreement and shall not limit or affect the meaning or construction of the terms and conditions hereof. Words such as herein,
hereinafter, hereof and hereunder refer to this Agreement as a whole and not merely to a section or paragraph
in which such words appear, unless the context otherwise requires. The singular shall include the plural, and each masculine, feminine
and neuter reference shall include and refer also to the others, unless the context otherwise requires.

 

13.8 Entire Agreement. This Agreement
(including Exhibit A and the Protocol) represents the entire and integrated agreement between the Parties and supersedes
all prior negotiations, representations or agreements, either written or oral, regarding its subject matter

 

13.9 Conflict or Inconsistency. In
case of a conflict between this Agreement and the Protocol, this Agreement shall control. The parties agree that they have participated
equally in the formation of this Agreement and that the language and terms of this Agreement shall not be construed against any
party by reason of the extent to which such party or its professional advisors participated in the preparation of this Agreement.

 

13.10 Counterparts. This Agreement
and any Work Order may be executed in one or more counterparts, including .PDF copies or counterparts submitted by facsimile, each
of which shall be deemed an original and all of which shall constitute the same instrument.

 

13.11 Further Assurances. Each party
covenants and agrees that, subsequent to the execution and delivery of this Agreement and without any additional consideration,
it will execute and deliver any further legal instruments and perform any acts which are or may become reasonably necessary to
effectuate the purposes of this Agreement.

 

(signature
page follows]

 

    	21

    	 

    

 

IN WITNESS WHEREOF the parties have caused this Agreement
to be executed on their behalf by their duly authorized representatives intending it to take effect as an instrument under seal
as of the Effective Date.

 

 

 

    	22

    	 

    

CONFIDENTIAL

DO NOT REPRODUCE OR DISCLOSE

 

Exhibit A

BUDGET, PAYMENT TERMS AND PAYMENT SCHEDULE

[BUDGET TO BE ATTACHED]

 

1.0 Payment Terms.

 

1.1
The Budget set forth herein is based on the specific charges applicable for the services of the Institution and/or Investigator.
Sponsor shall pay to DCR the amounts specified in The Budget in accordance with the payment schedule outlined in the Payment Schedule
outlined below in section 2.0. DCR shall then pay the Institution and/or Investigator monthly payments upon entry of completed
study activities into the Clinical Trial Management System (CTMS). The parties acknowledge and agree that the terms and conditions
of The Budget are confidential and shall be treated as Confidential Information in accordance with the provisions of Section 4
of this Agreement. Payments will be reconciled as a part of the financial reconciliation at the time of the final payment set
forth in the Payment Schedule.

 

1.2
In the event of an amendment to the Protocol that modifies the services to be provided under this Agreement, Sponsor and DCR shall
negotiate any modification to the payments hereunder in an amount equal to the services added or eliminated by the Protocol amendment
and agree to this change in writing (email is sufficient). Furthermore, pricing for Institution and/or Investigator services may
be subject to change in accordance with any change in Study scope. Completed-visit-per-Subject payment due, including any screen
failure payments that may be payable under the terms of this Agreement, will be made based upon prior month enrollment data as
entered into the DCR Clinical Trial Management System (CTMS). All screen failures will be paid at the screening rate. DCR shall,
at its discretion, verify and reconcile this enrollment data with Sponsor, and appropriate payment adjustments from Sponsor shall
be made on the presentation of an invoice from DCR, or as to Study Site, at DCR's discretion. Sponsor or designee shall provide
proper documentation necessary to complete said reconciliation.

 

1.3
All amounts required to be paid by DCR to Institution and/or Investigator under this Agreement are exclusive of any and all duties
and taxes, however designated, levied or based on this Agreement or the Services delivered hereunder, including, without limitation,
any personal property, retail sales, goods and services, use or value added taxes and whether such taxes are now in force or subsequently
levied. Sponsor shall pay and be responsible for all such taxes (excluding taxes based on DCR's net income and the Federal Insurance
Contributions Act, workers' compensation, unemployment and withholding taxes concerning DCR personnel). Sponsor shall promptly
reimburse DCR for any such taxes which DCR pays directly.

 

    	23

    	 

    

 

 

 

[*] This material has been omitted
pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	24

    	 

    

 

FIRST AMENDMENT
TO WORK ORDER #01

 

This First Amendment (the
"Amendment") to Work Order #01 (the "Work Order") is made and entered into effective as of the 71h
day of January, 2015, (the "Effective Date") by and between Aethlon Medical Inc. with offices located at 8910 University
Center Lane, Suite 660, San Diego, CA 92122 (hereinafter referred to as "Sponsor"), and Total Renal Research,
Inc. d/b/a DaVita Clinical Research with offices located at 825 South 8th Street, Suite 300, Minneapolis, MN 55404 ("DCR").
Sponsor and DCR shall each be hereinafter referred to as a "Party" and collectively as the "Parties".

 

WHEREAS, the Parties entered into the Work Order on the 16th day of May, 2014, pursuant to the Master Services Agreement
effective the 14th day of February, 2014 (the "Agreement");

 

WHEREAS, the Parties wish to amend the terms of the Work
Order as outlined in this Amendment;

 

NOW, THEREFORE, in consideration of the mutual
promises and covenants in the Agreement, Work Order and this Amendment, the Parties agree as follows:

 

	1.	Attachment 3, Study Conduct and Site Management Services Budget is hereby deleted in its entirety and replaced with the attached Study Conduct and Site Management Services Budget to reflect the addition of:
	 	 	·     Study
Subject travel expense reimbursement
	 	 	·     Central
lab identification assistance and protocol amendment review
	 	 	·     IStat
Celite Act Cartridges procurement
	 	 	 
	2.	Sponsor hereby agrees that DCR shall procure, and Sponsor shall pay for, the iStat Celite Act Cartridges ("Cartridges") for use in the Study. Cartridges will be procured in quantities of twenty-five (25) Cartridges per box. DCR shall invoice Sponsor, and Sponsor shall reimburse DCR, the current market price of each box of Cartridges. Any unused Cartridges shall, at Sponsor's expense, be shipped to Sponsor or destroyed, as requested by Sponsor in writing (for which email shall suffice). In addition, DCR shall invoice and Sponsor shall pay to DCR an administrative fee of XXXXXXXX* of the total cost of each Cartridge box procured for the Study. Sponsor shall pay DCR in accordance with the terms of the Agreement and Work Order.

 

	3.	Except as stated in this Amendment all terms and conditions of the Agreement and Work Order remain in full force and effect.

 

 

Signature page follows

 

 

 

[*] This material has been omitted pursuant
to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	25

    	 

    

 

 

 

    	26

    	 

    

 

 

 

[*] This material has been omitted pursuant
to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

 

    	27

    	 

    

 

 

 

[*] This material has been omitted pursuant
to a request for confidential treatment and filed separately with the Securities and Exchange Commission.

    	28Exhibit
10.1

 

LICENSE
AGREEMENT

 

 

between

 

UNIQUE
GROWING SOLUTIONS, INC.

(f/k/a
Alternative Energy & Environmental Solutions, Inc.) 

 

 

and

 

 

LAMINA
EQUITIES CORPORATION

 

 

 

Dated
February 25, 2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

 

LICENSE
AGREEMENT

 

This
License Agreement (the “Agreement”) is made and entered into February 25, 2015 (the “Effective
Date”) by and between Lamina Equities Corporation, a Nevada corporation (“Lamina”) and Unique Growing
Solutions, Inc. (f/k/a Alternative Energy & Environmental Solutions, Inc.), a Nevada corporation (“ALNE”).
Lamina and ALNE are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

Recitals

 

WHEREAS,
Lamina owns or Controls certain intellectual property relating to diagnosing illness in humans via a saliva test; and

 

WHEREAS,
Lamina wishes to license to ALNE, and ALNE wishes to license from Lamina, through the license grants contemplated herein, such
intellectual property rights to develop and commercialize Products (as defined below) in accordance with the terms and conditions
set forth below.

 

NOW,
THEREFORE, in consideration of the premises and the mutual promises and conditions hereinafter set forth, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound,
do hereby agree as follows:

 

ARTICLE
1

DEFINITIONS

 

Unless
otherwise specifically provided herein, the following terms shall have the following meanings:

 

1.1              “Affiliate”
means, with respect to a Party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled
by or is under common control with such Party. For purposes of this definition, “control” and, with correlative meanings,
the terms “controlled by” and “under common control with”, means (i) the possession, directly or
indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities,
by contract relating to voting rights or corporate governance, or otherwise; or (ii) the ownership, directly or indirectly,
of more than fifty percent (50%) of the voting securities or other ownership interest of a business entity (or, with respect to
a limited partnership or other similar entity, its general partner or controlling entity). The Parties acknowledge that in the
case of certain entities organized under the laws of certain countries outside of the United States, the maximum percentage ownership
permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage shall
be substituted in the preceding sentence, provided that such foreign investor has the power to direct the management or
policies of such entity.

 

1.2              “ALNE”
has the meaning set forth in the preamble hereto.

 

    	2

    	 

    

 

1.3              “Applicable
Law” means federal, state, local, national and supra-national laws, statutes, rules, and regulations, including
any rules, regulations, guidelines, or other requirements of the Regulatory Authorities, major national securities exchanges or
major securities listing organizations, that may be in effect from time to time during the Term and applicable to a particular
activity.

 

1.4              “Business
Day” means a day other than a Saturday or Sunday on which banking institutions in New York, New York are open for business.

 

1.5              “Calendar
Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October
1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior
to the first to occur of January 1, April 1, July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall
end on the last day of the Term.

 

1.6              “Calendar
Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31,
except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which
the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends
and end on the last day of the Term.

 

1.7              “Change
in Control” means with respect to a Party: (1) the sale of all or substantially all of such Party’s assets or
business relating to this Agreement; (2) a merger, reorganization or consolidation involving such Party in which the holders of
voting securities of such Party outstanding immediately prior thereto cease to hold voting securities that represent at least
fifty percent (50%) of the combined voting power of the surviving entity immediately after such merger, reorganization or consolidation;
or (3) a person or entity, or group of persons or entities, acting in concert acquire more than fifty percent (50%) of the voting
equity securities or management control of such Party.

 

1.8              “Commercial
Sublicensee” means a Sublicensee to whom ALNE has granted a right to offer for sale, have sold or sell one or more Products
in all or a portion of the Territory including exclusive distributors.

 

1.9              “Commercialization”
means any and all activities directed to the preparation for sale of, offering for sale of, or sale of a Product, including activities
related to marketing, promoting, distributing, and importing such Product, and interacting with Regulatory Authorities regarding
any of the foregoing. When used as a verb, “to Commercialize” and “Commercializing” means
to engage in Commercialization, and “Commercialized” has a corresponding meaning.

 

1.10           “Commercially
Reasonable Efforts” means, with respect to the objective that is the subject of such efforts, such reasonable,
good faith efforts and resources as a similarly-situated (including in relation to size and personnel and other resources) company
within the pharmaceutical industry would normally use to accomplish a similar objective under similar circumstances.

 

1.11           “Confidential
Information” means any technical, business, or other information or data provided orally, visually, in writing or other
form by or on behalf of one Party to the other Party in connection with this Agreement, including information relating to the
terms of this Agreement, any Product (including the Regulatory Documentation), any Exploitation of any Product, any know-how with
respect thereto developed by or on behalf of the disclosing Party or its Affiliates, or the scientific, regulatory or business
affairs or other activities of either Party.

 

    	3

    	 

    

 

1.12           “Control”
means, with respect to any item of Information, Regulatory Documentation, material, Patent, or other property right existing on
or after the Effective Date and during the Term, possession of the right, whether directly or indirectly, and whether by ownership,
license or otherwise (other than by operation of the license and other grants in Section 2.1), to grant a license, sublicense
or other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation,
material, Patent, or other property right as provided for herein without violating the terms of any agreement or other arrangement
with any Third Party.

 

1.13           “Development”
means all activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing,
toxicology, formulation, process development, manufacturing scale-up, qualification and validation, quality assurance/quality
control, clinical studies, statistical analysis and report writing, the preparation and submission of Drug Approval Applications,
regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested
or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When used
as a verb, “Develop” means to engage in Development.

 

1.14           “Development
Data” means all non-clinical, clinical, technical, chemical, safety, and scientific data and information and other results,
including relevant laboratory notebook information, screening data, and synthesis schemes, including descriptions in any form,
data and other information, in each case, that is generated by or resulting from or in connection with the conduct of Development
of Products.

 

1.15           “Dollars”
or “$” means United States Dollars.

 

1.16           “Drug
Approval Application” means a New Drug Application (an “NDA”) as defined in the FFDCA, or any corresponding
foreign application, including, with respect to the European Union, a Marketing Authorization Application filed with the EMA or
with the applicable Regulatory Authority of a country in Europe with respect to the mutual recognition or any other national approval
procedure.

 

1.17           “Effective
Date” means the effective date of this Agreement as set forth in the preamble hereto.

 

1.18           “EMA”
means the European Medicines Agency and any successor agency or authority having substantially the same function.

 

1.19           “Exploit”
means to make, have made, import, use, sell, or offer for sale, including to research, Develop, Commercialize, Manufacture, have
Manufactured, obtain Regulatory Approval for, hold, or keep (whether for disposal or otherwise), have used, export, transport,
distribute, promote, market, or have sold or otherwise dispose of on a worldwide basis. “Exploitation” shall
mean the act of Exploiting.

 

    	4

    	 

    

 

1.20           “FDA”
means the United States Food and Drug Administration and any successor agency or agencies or authority having substantially the
same function.

 

1.21           “FFDCA”
means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §301 et seq., as amended from time to time,
together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions,
and modifications thereto).

 

1.22           “First
Commercial Sale” means, with respect to a Product and a country, the first sale by ALNE, its Affiliate or its Commercial
Sublicensee to a Third Party for monetary value of such Product in such country after Regulatory Approval for such Product has
been obtained in such country.

 

1.23           “IND”
means an application filed with a Regulatory Authority for authorization to commence human clinical studies, including (a) an
Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b)
any equivalent of a United States IND in other countries or regulatory jurisdictions, and (c) all supplements, amendments,
variations, extensions and renewals thereof that may be filed with respect to the foregoing.

 

1.24           “Information”
means all technical, scientific, and other know-how and information, trade secrets, knowledge, technology, means, methods, processes,
practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological,
chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing
and quality control data and information, including study designs and protocols, assays, biological methodology, other data relating
to Development, all data, information and materials relating to Commercialization, including customer lists (both actual and target
customers), any market studies and competitive data; in each case (whether or not confidential, proprietary, patented or patentable)
in written, electronic or any other form now known or hereafter developed.

 

1.25           “Invention”
means any writing, invention, discovery, improvement, technology, Information or other Know-How (in each case, whether patented
or not) that is not existing as of the Effective Date and is invented under this Agreement during the Term.

 

1.26           “LIBOR”
means the London Interbank Offered Rate for deposits in United States Dollars having a maturity of one month published by the
British Bankers’ Association, as adjusted from time to time on the first London business day of each month.

 

1.27           “Lamina”
has the meaning set forth in the preamble hereto.

 

1.28           “Lamina
Know-How” means all Information Controlled by Lamina or any of its Affiliates as of the Effective Date or at any time
during the Term (subject to Section 9.2.2) that is not generally known and is necessary or reasonably useful for
the Development, manufacture, or Commercialization of a Product.

 

    	5

    	 

    

 

1.29           “Liens”
means any and all liens, encumbrances, charges, security interests, options, claims, mortgages, pledges, or agreements, obligations,
understandings or arrangements or other restrictions on title or transfer of any nature whatsoever.

 

1.30           “Manufacture”
or “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing,
packaging, labeling, shipping and holding of a Product or any intermediate thereof, including clinical and commercial manufacture.

 

1.31           “NDA”
has the meaning set forth in the definition of “Drug Approval Application.”

 

1.32           “Net
Sales” means, with respect to a Product for any period, the total amount billed or invoiced on sales of such Product
during such period by ALNE, its Affiliates, or Sublicensees to Third Parties, less the following normal and customary bona-fide
deductions and allowances actually taken:

 

1.32.1  trade,
cash and quantity discounts;

 

1.32.2  price
reductions, refunds or rebates, retroactive or otherwise, imposed by, negotiated with or otherwise paid (whether in cash or trade)
to governmental authorities or third party payors;

 

1.32.3  taxes
on sales (such as sales, value added, or use taxes) and customs and excise duties and other duties related to sale, in each case,
to the extent such taxes are included in the gross amount invoiced;

 

1.32.4  wholesale
and distribution fees, deductions and prompt pay discounts;

 

1.32.5  bad
debts not exceeding five percent (5%) of the value of the sales of Product during the then-current Calendar Year, provided that
any recovery of bad debts shall be deemed a sale for purposes of this definition of “Net Sales”;

 

1.32.6  amounts
repaid, deducted or credited by reason of rejections, defects, recalls or returns, or because of retroactive price reductions,
including rebates or wholesaler charge backs; and

 

1.32.7  freight,
insurance, and other transportation charges to the extent added to the sale price and set forth separately as such in the total
amount invoiced.

 

Notwithstanding
the foregoing, Net Sales shall not include transfers or dispositions for charitable, pre-clinical, clinical, regulatory, or governmental.
To the extent that ALNE, its Affiliate or any Commercial Sublicensee sells a Product, on an arms-length basis, to any Sublicensee
who is not an Affiliate of such selling Person for resale, only the initial sale of such Product by ALNE, its Affiliate, or its
Commercial Sublicensee shall constitute a sale for purposes of determining Net Sales. Except as contemplated by the immediately
foregoing sentence, Net sales shall not include sales between or among ALNE, its Affiliates, or Sublicensees. Net Sales shall
be calculated in accordance with the standard internal policies and procedures of ALNE, its Affiliates, or Sublicensees, which
must be in accordance with United States Generally Accepted Accounting Principles or International Financial Reporting Standards
as applicable.

 

    	6

    	 

    

 

1.33           “Party”
and “Parties” has the meaning set forth in the preamble hereto.

 

1.34           “Patents”
means (i) all national, regional and international patents and patent applications, including provisional patent applications;
(ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application
claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals
and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from the foregoing
patent applications ((i) and (ii)), including utility models, petty patents and design patents and certificates of invention;
(iv) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations,
reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents
or patent applications ((i), (ii), and (iii)); and (v) any similar rights, including so-called pipeline protection or any
importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing
patent applications and patents.

 

1.35           “Person”
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, unincorporated association, foundation, joint venture or other
similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.36           “Product”
means any pharmaceutical product or medical device, whether prescription or over-the-counter, marketed for diagnosing illness
in humans via a saliva test; provided, however, that “Product” shall not refer to any product Controlled,
developed, manufactured, marketed, sold, offered for sale, exported, or imported directly or indirectly by a Sublicensee if such
Sublicensee’s rights in respect of such product were obtained or developed independently of any sublicense or right granted
by ALNE hereunder.

 

1.37           “Regulatory
Approval” means, with respect to a country or other jurisdiction, any and all approvals (including Drug Approval Applications),
licenses, registrations, or authorizations of any Regulatory Authority necessary to commercially distribute, sell, offer for sale,
market, import or use a Product in such country or other jurisdiction, including, where applicable, (i) pricing or reimbursement
approval in such country or other jurisdiction, (ii) pre- and post-approval marketing authorizations (including any prerequisite
Manufacturing approval or authorization related thereto), and (iii) labeling approval.

 

1.38           “Regulatory
Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local governmental
or regulatory agencies, departments, bureaus, commissions, councils, or other government entities (e.g., the FDA and EMA) regulating
or otherwise exercising authority with respect to activities contemplated in this Agreement, including the Exploitation of Products.

 

    	7

    	 

    

 

1.39           “Regulatory
Documentation” means all (i) applications (including all INDs and Drug Approval Applications), registrations, licenses,
authorizations, and approvals (including Regulatory Approvals); (ii) correspondence and reports submitted to or received
from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory
Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents,
adverse event files, and complaint files; and (iii) clinical and other data contained or relied upon in any of the foregoing,
in each case ((i), (ii), and (iii)) relating to a Product.

 

1.40           “Representatives”
means (actual or potential) Sublicensees, other Persons who have been granted rights to Exploit Products in accordance with this
Agreement, acquirers, financing sources, investors or permitted assignees under Section 9.3 and to their financial and
legal advisors who have a need to know the Confidential Information in connection with any such sublicense, financing, investment,
acquisition or assignment.

 

1.41           “Sublicensee”
means a Person, other than an Affiliate, that is granted a sublicense by ALNE under a license granted in Section 2.1 or
a right by ALNE, its Affiliates or Commercial Sublicensees to sell a Product, offer a Product for sale, or have a Product sold
(each such sublicense or right, a “Sublicense”).

 

1.42           “Territory”
means worldwide.

 

1.43           “Third
Party” means any Person other than Lamina, ALNE and their respective Affiliates.

 

1.44           “United
States” means the United States of America and its territories and possessions (including the District of Columbia and
Puerto Rico).

 

Additional
Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:

 

	Term	 	Section
	“ALNE Indemnitees”	 	7.2
	“Breaching Party”	 	8.3
	“Default Notice”	 	8.3
	“Follow-On Product”	 	5.2.5
	“Force Majeure”	 	9.1
	“Lamina Indemnitees”	 	7.1
	“Losses”	 	7.1
	“Non-Breaching Party”	 	8.3
	“Sublicense”	 	1.41
	“Term”	 	8.1
	“Third Party Claims”	 	7.1

 

    	8

    	 

    

 

ARTICLE
2

TRANSFER
AND ASSIGNMENT; GRANT OF RIGHTS

 

2.1             Grants
to ALNE. Subject to the terms and conditions of this Agreement, Lamina hereby grants to ALNE an exclusive (including
with regard to Lamina) worldwide license, with the right to grant sublicenses in accordance with Section 2.2, under the
Lamina Know-How.

 

2.2             Sublicenses.

 

2.2.1   Right
to Grant Sublicenses. ALNE shall have the right to grant Sublicenses (through multiple tiers of Sublicensees). ALNE
shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement. ALNE shall remain responsible
for the performance of its Affiliates and Sublicensees that are granted Sublicenses as permitted herein, and the grant of any
such Sublicense shall not relieve ALNE of its obligations under this Agreement. With respect to any such Sublicense, ALNE shall
ensure that the agreement pursuant to which it grants such Sublicense (i) does not conflict with the terms and conditions of this
Agreement and (ii) contains terms obligating the Sublicensee to comply with confidentiality and non-use provisions consistent
with those set forth in this Agreement.

 

2.2.2   Termination
of Sublicenses. In the event of termination of this Agreement, in whole or in part, any sublicense granted by ALNE pursuant
to this Section 2.2 shall automatically be deemed to terminate to the same extent as the other terms and conditions of
this Agreement terminate.

 

2.3             No
Other Rights Granted by Lamina. Except as expressly provided herein and without limiting the foregoing, Lamina grants
no other right or license, including any rights or licenses to the Lamina Know-How, the Regulatory Documentation, or any other
intellectual property rights not otherwise expressly granted herein.

 

2.4             Transfer
of Lamina Know-How. As soon as practicable after the Effective Date, Lamina shall provide to ALNE (which can be in the form
of copies and electronic files) all material Lamina Know-How existing as of the Effective Date.

 

2.5             Compliance
with Law. ALNE shall conduct, or cause to be conducted, the Development, Commercialization, Manufacture and Exploitation of
Products in compliance with all Applicable Laws.

 

ARTICLE
3

PAYMENTS
AND RECORDS

 

3.1             Upfront
Payment. On the Effective Date, ALNE shall pay Lamina an upfront amount equal to One Thousand Dollars ($1,000). Such payment
shall be nonrefundable and noncreditable against any other payments due hereunder.

 

3.2             Regulatory
Milestones. In partial consideration of the rights granted by Lamina to ALNE hereunder and subject to the terms and conditions
set forth in this Agreement, ALNE shall pay to Lamina a milestone payment within thirty (30) days after the achievement of each
of the following milestones:

 

3.2.1   ALNE’s
first receipt of notice from the FDA that an NDA in respect of a Product has received approval, Four Thousand Dollars ($4,000);

 

    	9

    	 

    

 

3.2.2   First
Commercial Sale of a Product in the United States, Five Thousand Dollars ($5,000);

 

3.2.3   First
Commercial Sale of a Product in any country or territory outside the United States after receipt of all requisite Regulatory Approvals
in such country, One Thousand Dollars ($1,000);

 

Each milestone
payment in this Section 3.2 shall be payable only upon the first achievement of such milestone and no amounts shall be
due for subsequent or repeated achievements of such milestone, whether for the same or a different Product. The maximum aggregate
amount payable by ALNE pursuant to this Section 3.2 is Ten Thousand Dollars ($10,000).

 

3.3             Royalty.
As further consideration for the rights granted to ALNE hereunder, commencing upon the First Commercial Sale, ALNE shall pay to
Lamina a royalty on Net Sales of 7.5% during each Calendar Year.

 

3.4             Mode
of Payment. All payments under this Agreement shall be made by deposit of Dollars in the requisite amount to such bank
account as Lamina may from time to time designate by notice to ALNE. For the purpose of calculating any sums due under, or otherwise
reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars),
a Party shall convert any amount expressed in a foreign currency into Dollar equivalents using an exchange rate to be mutually
agreed upon by the Parties.

 

3.5             Taxes.
The milestones payable by ALNE to Lamina pursuant to this Agreement shall be paid free and clear of any and all taxes, except
for any withholding taxes required by Applicable Law.

 

3.6             Interest
on Late Payments. If any payment due to Lamina under this Agreement is not paid when due, then ALNE shall pay interest
thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of one percent above LIBOR,
such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest.

 

ARTICLE
4

INTELLECTUAL
PROPERTY

 

4.1             Ownership
of Intellectual Property.

 

4.1.1   Ownership
of Technology. As between the Parties, each Party shall own and retain all right, title, and interest in and to any
and all Inventions and Information that are conceived, discovered, developed, or otherwise made solely by or on behalf of such
Party (or its Affiliates or Sublicensees) under or in connection with this Agreement, whether or not patented or patentable, and
any and all Patents and other intellectual property rights with respect thereto.

 

4.1.2   United
States Law. The determination of whether Information and Inventions are conceived, discovered, developed, or otherwise
made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other intellectual property rights)
therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States as such law exists
as of the Effective Date irrespective of where such conception, discovery, development or making occurs.

 

    	10

    	 

    

 

4.1.3   Assignment
Obligation. Each Party shall cause all Persons who perform activities for such Party under this Agreement to be under
an obligation to assign their rights in any Inventions resulting therefrom to such Party.

 

ARTICLE
5

CONFIDENTIALITY
AND NON-DISCLOSURE

 

5.1             Confidentiality
Obligations. At all times during the Term and for a period of ten (10) years following termination or expiration hereof
in its entirety, each Party shall, and shall cause its Affiliates, and its and their respective officers, directors, employees
and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for
any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party,
except to the extent such disclosure or use is expressly permitted by the terms of this Agreement or is reasonably necessary or
useful for the performance of a Party’s obligations, or the exercise of a Party’s rights, under this Agreement. Notwithstanding
the foregoing, but to the extent the receiving Party can demonstrate by documentation or other competent proof, the confidentiality
and non-use obligations under this Section 5.1 with respect to any Confidential Information shall not include any information
that:

 

5.1.1   has
been published by a Third Party or is or hereafter becomes part of the public domain by public use, publication, general knowledge
or the like through no wrongful act, fault or negligence on the part of the receiving Party;

 

5.1.2   has
been in the receiving Party’s possession prior to disclosure by the disclosing Party without any obligation of confidentiality
with respect to such information;

 

5.1.3   is
subsequently received by the receiving Party from a Third Party without restriction and without breach of any agreement between
such Third Party and the disclosing Party; or

 

5.1.4   has
been independently developed by or for the receiving Party without reference to, or use or disclosure of the disclosing Party’s
Confidential Information.

 

Specific
aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the
receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in
the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered in the public
domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in
the public domain or in the possession of the receiving Party unless the combination and its principles are in the public domain
or in the possession of the receiving Party.

 

    	11

    	 

    

 

5.2             Permitted
Disclosures. Each Party may disclose Confidential Information to the extent that such disclosure is:

 

5.2.1   in
the reasonable opinion of the receiving Party’s legal counsel, required to be disclosed pursuant to Applicable Law or made
in response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state,
provincial and local governmental or regulatory body of competent jurisdiction, including by reason of filing with securities
regulators; provided, however, that the receiving Party, to the extent practicable and legally permissible, shall first have given
prompt written notice (and to the extent practicable and legally permissible, at least five (5) Business Days’ notice) to
the disclosing Party and given the disclosing Party a reasonable opportunity to take whatever action it deems necessary to protect
its Confidential Information (for example, quash such order or to obtain a protective order or confidential treatment requiring
that the Confidential Information and documents that are the subject of such order be held in confidence by such court or regulatory
body or, if disclosed, be used only for the purposes for which the order was issued). In the event that no protective order or
other remedy is sought or obtained, or the disclosing Party waives compliance with the terms of this Agreement, receiving Party
shall furnish only that portion of Confidential Information which receiving Party is advised by counsel is legally required to
be disclosed;

 

5.2.2   made
by or on behalf of the receiving Party to Regulatory Authorities as required in connection with any filing, application or request
for Regulatory Approval in accordance with the terms of this Agreement; provided, however, that reasonable measures
shall be taken to assure confidential treatment of such information to the extent practicable and consistent with Applicable Law;

 

5.2.3   made
to its Representatives; provided that any such recipient of such Confidential Information agrees to be bound by the confidentiality
and non-use restrictions contemplated hereby; provided, further that the Party making such disclosure shall remain responsible
for any failure by any such Person to treat such Confidential Information as required under this Article 5.

 

5.2.4   made
to its or its Affiliates’ financial and legal advisors who have a need to know such Confidential Information and are either
under professional codes of conduct giving rise to expectations of confidentiality and non-use or under written agreements of
confidentiality and non-use, in each case, at least as restrictive as those set forth in this Agreement; provided that the receiving
Party shall remain responsible for any failure by such financial and legal advisors and other Persons contemplated by this Section
5.2.4, to treat such Confidential Information as required under this Article 5.

 

5.3             Public
Announcements. Except as contemplated by Section 5.4 or as otherwise agreed by the Parties, neither Party shall issue
any other public announcement, press release, or other public disclosure regarding this Agreement or its subject matter without
the other Party’s prior written consent, except for any such disclosure that is, in the opinion of the disclosing Party’s
counsel, required by Applicable Law (including, without limitation, public disclosure on a Quarterly Report on Form 10-Q, an Annual
Report on Form 10-K, or a Current Report on Form 8-K) or the rules of a stock exchange on which the securities of the disclosing
Party are listed or for information which has previously been made public. In the event a Party is, in the opinion of its counsel,
required by Applicable Law or the rules of a stock exchange on which its securities are listed to make such a public disclosure,
such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable so as
to provide a reasonable opportunity to comment thereon and such required Party shall consider all comments from such other Party
in good faith.

 

    	12

    	 

    

 

5.4             Publications.
Each Party recognizes that the publication of papers regarding results of and other information regarding activities under this
Agreement may be beneficial to the Development and Commercialization of Products. Accordingly, ALNE and its Affiliates and Sublicensees
shall have the right to publish or present or permit the publication or presenting of papers and presentations that contain clinical
data regarding, or pertain to results of clinical testing of, Products (each, a “Publication”); provided, however,
that such publications do not contain the Confidential Information of Lamina and Lamina shall be provided with a copy of any such
Publication in advance of public publication or presentation thereof and ALNE shall consider in good faith any comments Lamina
may have with respect thereto.

 

5.5             Return
of Confidential Information. Upon the effective date of the termination of this Agreement for any reason, either Party
may request in writing, and the other Party shall either, with respect to Confidential Information to which such first Party does
not retain rights under the surviving provisions of this Agreement: (i) promptly destroy all copies of such Confidential
Information in the possession of the other Party and confirm such destruction in writing to the requesting Party; or (ii) promptly
deliver to the requesting Party, at the other Party’s expense, all copies of such Confidential Information in the possession
of the other Party; provided, however, the other Party shall be permitted to retain one (1) copy of such Confidential Information
for the sole purpose of performing any continuing obligations hereunder or for archival purposes. Notwithstanding the foregoing,
such other Party also shall be permitted to retain such additional copies of or any computer records or files containing such
Confidential Information that have been created solely by such Party’s automatic archiving and back-up procedures, to the
extent created and retained in a manner consistent with such other Party’s standard archiving and back-up procedures, but
not for any other use or purpose.

 

5.6             Survival.
All Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section
5.1.

 

ARTICLE
6

REPRESENTATIONS
AND WARRANTIES

 

6.1             Mutual
Representations and Warranties. Lamina and ALNE each represents and warrants to the other, as of the Effective Date, and covenants,
as follows:

 

6.1.1   Organization.
It is duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all
requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.

 

6.1.2   Authorization.
The execution and delivery of this Agreement and the performance by it of its obligations contemplated hereby have been duly authorized
by all necessary corporate action, and do not violate (i) such Party’s charter documents, bylaws, or other organizational
documents, (ii) in any material respect, any agreement, instrument, or contractual obligation to which such Party is bound,
(iii) any requirement of any Applicable Law, or (iv) any order, writ, judgment, injunction, decree, determination, or
award of any court or governmental agency presently in effect applicable to such Party.

 

    	13

    	 

    

 

6.1.3   Binding
Agreement. This Agreement is a legal, valid, and binding obligation of such Party enforceable against it in accordance with
its terms and conditions, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the
enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles
of equity (whether enforceability is considered a proceeding at law or equity).

 

6.1.4   Consents
and Approvals. No consent, approval, waiver, order or authorization of, or registration, declaration or filing with, any Third
Party is required in connection with the execution, delivery and performance of this Agreement by such Party or the performance
by such Party of its obligations contemplated hereby or thereby.

 

6.1.5   No
Inconsistent Obligation. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is
inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment
of its obligations hereunder.

 

6.2             Additional
Representations and Warranties of Lamina. Lamina further represents and warrants to ALNE, as of the Effective Date, and covenants,
as follows:

 

6.2.1   Lamina
has the right to grant the licenses specified herein.

 

6.2.2   Lamina
is the sole and exclusive owner of the entire right, title and interest in the Lamina Know-How. Such rights are not subject to
any Liens in favor of, or claims of ownership by, any Third Party.

 

6.2.3   To
Lamina’s knowledge, the Exploitation by ALNE and its Affiliates and Sublicensees hereunder of the Products will not infringe
any Patent or other intellectual property or proprietary right of any Person.

 

6.2.4   The
conception, development and reduction to practice of the Lamina Know-How existing as of the Effective Date have not constituted
or involved the misappropriation of trade secrets or other rights or property of any Person. There are no claims, judgments or
settlements against or amounts with respect thereto owed by Lamina or any of its Affiliates relating to the existing Regulatory
Filings or the Lamina Know-How.

 

6.2.5   To
its knowledge, Lamina has conducted, and its contractors and consultants have conducted, all Development with respect to the Product
that it has conducted prior to the Effective Date in accordance with good laboratory practice and good clinical practices, as
applicable and defined by the FDA, and Applicable Law.

 

    	14

    	 

    

 

6.2.6   Neither
Lamina nor any of its Affiliates, nor any of its or its Affiliates’ directors or officers has been debarred or is subject
to debarment and neither Lamina nor any of its Affiliates will use in any capacity, in connection with the services to be performed
under this Agreement, any Person who has been debarred pursuant Lamina Section 306 of the FFDCA or who is the subject of a conviction
described in such section. Lamina shall inform ALNE in writing immediately if it or any Person who is performing services hereunder
is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or legal or
administrative proceeding is pending or, to the best of Lamina’s knowledge, is threatened, relating to the debarment or
conviction of Lamina or any Person performing services on behalf of Lamina hereunder.

 

6.2.7   To
Lamina’s knowledge, no Person is misappropriating or threatening to misappropriate the Lamina Know-How.

 

6.2.8   Lamina
has prepared, maintained or retained all material Regulatory Documentation required to be maintained or reported pursuant to and
in accordance with the applicable requirements of good laboratory practices and good clinical practices, as applicable, as defined
by the FDA, to the extent required, and Applicable Law, and such Regulatory Documentation does not contain any materially false
or misleading statements.

 

6.3             DISCLAIMER
OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES,
EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY
OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY, OR FITNESS
FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES.

 

ARTICLE
7

INDEMNITY

 

7.1             Indemnification
of Lamina. ALNE shall indemnify Lamina, its Affiliates and its and their respective directors, officers, employees,
and agents (“Lamina Indemnitees”), and defend and save each of them harmless, from and against any and all
losses, damages, liabilities, penalties, costs, and expenses (including attorneys’ fees and expenses) (collectively, “Losses”)
in connection with any and all suits, investigations, claims, or demands of Third Parties (collectively, “Third Party
Claims”) incurred by or rendered against the Lamina Indemnitees arising from or occurring as a result of: (i) the
breach by ALNE of this Agreement, (ii) the gross negligence or willful misconduct on the part of ALNE or its Affiliates or
Sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees, and agents
in performing its or their obligations under this Agreement, or (iii) the Exploitation by ALNE or any of its Affiliates or Sublicensees
or its or their distributors or contractors of any Product, except to the extent Lamina has an obligation to indemnify ALNE Indemnitees
pursuant to Section 7.2 for such Losses and Third Party Claims.

 

    	15

    	 

    

 

7.2             Indemnification
of ALNE. Lamina shall indemnify ALNE, its Affiliates and its and their respective directors, officers, employees, and
agents (the “ALNE Indemnitees”), and defend and save each of them harmless, from and against any and all Losses
in connection with any and all Third Party Claims incurred by or rendered against the ALNE Indemnitees arising from or occurring
as a result of: (i) the breach by Lamina of this Agreement, (ii) the gross negligence or willful misconduct on the part of
Lamina or its Affiliates or its or their respective directors, officers, employees, and agents in performing its obligations under
this Agreement, (iii) any claim by any current or former Lamina shareholder, investor or contributor that any ALNE Indemnitee
or any Sublicensee owes such Person any compensation in relation to the Exploitation of the Products or the rights granted hereunder,
or (iv) Lamina’s or its Affiliate’s or subcontractor’s violation of any Applicable Law, or gross negligence
or willful misconduct, in relation to the Exploitation of Products prior to the Effective Date, except to the extent ALNE has
an obligation to indemnify Lamina Indemnitees pursuant to Section 7.1 for such Losses and Third Party Claims.

 

7.3             Special,
Indirect, and Other Losses. EXCEPT IN THE EVENT OF A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 5, AND EXCEPT
TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION
UNDER THIS ARTICLE 7, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY,
PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS INTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY,
WHETHER IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY OUT OF THE
TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

ARTICLE
8

TERM
AND TERMINATION

 

8.1             Term.
This Agreement shall commence on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force
and effect until terminated in accordance with this Article 8 (such period, the “Term”).

 

8.2             ALNE
Termination for Convenience. ALNE shall have the right to terminate this Agreement in its sole discretion, either in
its entirety or in respect of one or more countries, at any time by providing sixty (60) days prior written notice to Lamina.

 

8.3             Termination
for Material Breach. If either Party (the “Non-Breaching Party”) believes that the other Party (the “Breaching
Party”) has materially breached one or more of its obligations under this Agreement, then the Non-Breaching Party may
deliver notice of such material breach to the Breaching Party specifying the nature of the alleged breach in reasonable detail
(a “Default Notice”). Thereafter, the Non-Breaching Party shall have the right to terminate this Agreement
if the breach asserted in such Default Notice has not been cured within sixty (60) days after such Default Notice.

 

8.4             Termination
for Insolvency. In the event that either Party (i) files for protection under bankruptcy or insolvency laws, (ii) makes
an assignment for the benefit of creditors, (iii) appoints or suffers appointment of a receiver or trustee over substantially
all of its property that is not discharged within ninety (90) days after such filing, (iv) proposes a written agreement of
composition or extension of its debts, (v) proposes or is a party to any dissolution or liquidation, (vi) files a petition
under any bankruptcy or insolvency act or has any such petition filed against that is not discharged within sixty (60) days of
the filing thereof, then the other Party may terminate this Agreement in its entirety effective immediately upon written notice
to such Party.

 

8.5             Effects
of Termination. In the event of a termination of this Agreement in its entirety by Lamina pursuant to Section 8.3
or by ALNE pursuant to Section 8.2:

 

8.5.1   all
rights and licenses granted by Lamina hereunder shall immediately terminate;

 

8.5.2   ALNE
shall, and hereby does, effective as of the effective date of termination, assign to Lamina at ALNE’s expense, all of its
right, title, and interest in and to all Regulatory Approvals applicable to any Product, and all Regulatory Documentation specific
to such Regulatory Approvals then owned by ALNE or any of its Affiliates, and shall use Commercially Reasonable Efforts to cause
any and all Sublicensees to assign to Lamina any such Regulatory Approvals and related Regulatory Documentation then owned by
such Sublicensee; and

 

8.5.3   at
Lamina’s request, assign to Lamina all right, title, and interest in and to the Development Data that ALNE is not precluded
from disclosing or assigning to Lamina pursuant to the terms of any applicable agreement with a Third Party; provided, however,
that ALNE shall use Commercially Reasonable Efforts (which shall not include any obligation to expend money) to obtain the consent
of the applicable Third Party for such disclosure and/or assignment in the event that ALNE is so precluded.

 

8.6             Remedies.
Except as otherwise expressly provided herein, termination of this Agreement (either in its entirety or with respect to one or
more country or countries) or other jurisdiction(s) in accordance with the provisions hereof shall not limit remedies that may
otherwise be available in law or equity.

 

8.7             Accrued
Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be without prejudice to any
rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration
shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.
Without limiting the foregoing, (i) Section 8.6 and this Section 8.7 and Articles 5, 7 and 9
of this Agreement shall survive the termination or expiration of this Agreement for any reason, (ii) Section 4.1 shall
survive any termination of this Agreement other than a termination by Lamina pursuant to Section 8.3 hereof or a termination
by ALNE pursuant to Section 8.2 hereof, (iii) Sections 3.5 through 3.7 shall survive a termination by ALNE
pursuant to Section 8.3 hereof, (iv) Article 3 shall survive a termination by ALNE pursuant to Section 8.4
hereof and (v) Section 8.5 shall survive any termination of this Agreement by Lamina pursuant to Section 8.3 hereof.
With respect to any Sections that survive in accordance with this Section 8.8, the corresponding definitions shall appropriately
survive (e.g. the definition of “Term” shall continue with respect to the above noted Sections and usage in other
definitions).

 

    	16

    	 

    

 

ARTICLE
9

MISCELLANEOUS

 

9.1             Force
Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under
or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay
is caused by or results from fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of
war (whether war be declared or not), terrorist acts, insurrections, riots, civil commotion, acts of God or acts, omissions, or
delays in acting by any Governmental Authority (except to the extent such delay results from the breach by the non-performing
Party or any of its Affiliates of any term or condition of this Agreement) or similar events beyond the reasonable control of
the non-performing Party (a “Force Majeure”). The non-performing Party shall notify the other Party of such
force majeure within thirty (30) days after such occurrence by giving written notice to the other Party stating the nature of
the event, its anticipated duration, and any action being taken to avoid or minimize its effect. The suspension of performance
shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use Commercially Reasonable
Efforts to remedy its inability to perform.

 

9.2             Assignment.

 

9.2.1   Without
the prior written consent of Lamina, ALNE shall not assign, delegate, or otherwise dispose of, whether voluntarily, involuntarily,
by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that ALNE
may make such an assignment without Lamina’s prior written consent to its Affiliate or to a successor, whether in a merger,
sale of stock, sale of assets or any other transaction, of all or substantially all the assets or business of ALNE or substantially
all of the assets or business of ALNE to which this Agreement relates. With respect to an assignment to an Affiliate, ALNE shall
remain responsible for the performance by such Affiliate of the rights and obligations hereunder. Without the prior written consent
of ALNE, Lamina shall not assign, delegate, or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or
otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that Lamina may make such an assignment
without ALNE’s prior written consent to its Affiliate or to a successor, whether in a merger, sale of stock, sale of assets
or any other transaction, of all or substantially all the assets or business of Lamina or substantially all of the assets or business
of Lamina to which this Agreement relates. With respect to an assignment to an Affiliate, Lamina shall remain responsible for
the performance by such Affiliate of the rights and obligations hereunder. Any attempted assignment or delegation in violation
of this Section 9.3 shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties
hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted assigns
of Lamina or ALNE, as the case may be. The permitted assignee or permitted transferee shall assume all obligations of its assignor
or transferor under this Agreement.

 

9.2.2   All
rights to Information, materials and intellectual property: (i) controlled by a Third Party permitted assignee of a Party,
which Information, materials and intellectual property were controlled by such assignee immediately prior to such assignment;
or (ii) controlled by an Affiliate of a Party who becomes an Affiliate through any Change in Control of or a merger, acquisition
(whether of all of the stock or all or substantially all of the assets of a Person or any operating or business division of a
Person) or similar transaction by or with the Party, which Information, materials and intellectual property were controlled by
such Affiliate immediately prior thereto, in each case ((i) and (ii)), shall be automatically excluded from the rights licensed
or granted to the other Party under this Agreement.

 

    	17

    	 

    

 

9.3             Severability.
If any provision of this Agreement is held to be illegal, invalid, or unenforceable under any present or future law, and if the
rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (i) such
provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable
provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force
and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance herefrom, and (iv) in
lieu of such illegal, invalid, or unenforceable provision, there shall be added automatically as a part of this Agreement a legal,
valid, and enforceable provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and
reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision
of law that would render any provision hereof illegal, invalid, or unenforceable in any respect.

 

9.4             Governing
Law. This Agreement or the performance, enforcement, breach or termination hereof shall be interpreted, governed by and construed
in accordance with the laws of Nevada, United States, excluding any conflicts or choice of law rule or principle that might otherwise
refer construction or interpretation of this Agreement to the substantive law of another jurisdiction; provided, that all questions
concerning the construction or effect of patent applications and patents shall be determined in accordance with the laws of the
country or other jurisdiction in which the particular patent application or patent has been filed or granted, as the case may
be.

 

9.5             Submission
to Jurisdiction; Waiver of Jury Trial.

 

9.5.1   IN
THE EVENT ANY PARTY TO THIS AGREEMENT COMMENCES ANY LITIGATION, PROCEEDING OR OTHER LEGAL ACTION IN CONNECTION WITH OR RELATING
TO THIS AGREEMENT, ANY RELATED AGREEMENT OR ANY MATTERS DESCRIBED OR CONTEMPLATED HEREIN OR THEREIN, WITH RESPECT TO ANY OF THE
MATTERS DESCRIBED OR CONTEMPLATED HEREIN OR THEREIN, THE PARTIES TO THIS AGREEMENT HEREBY (A) AGREE THAT ANY LITIGATION, PROCEEDING
OR OTHER LEGAL ACTION SHALL BE INSTITUTED IN A COURT OF COMPETENT JURISDICTION LOCATED WITHIN THE CITY OF LAS VEGAS, WHETHER A
STATE OR FEDERAL COURT; (B) AGREE THAT IN THE EVENT OF ANY SUCH LITIGATION, PROCEEDING OR ACTION, SUCH PARTIES WILL CONSENT AND
SUBMIT TO PERSONAL JURISDICTION IN ANY SUCH COURT DESCRIBED IN CLAUSE (A) OF THIS SECTION 9.5 AND TO SERVICE OF PROCESS
UPON THEM IN ACCORDANCE WITH THE RULES AND STATUTES GOVERNING SERVICE OF PROCESS (IT BEING UNDERSTOOD THAT NOTHING IN THIS SECTION
9.5 SHALL BE DEEMED TO PREVENT ANY PARTY FROM SEEKING TO REMOVE ANY ACTION TO A FEDERAL COURT IN THE CITY OF LAS VEGAS); AND
(C) AGREE TO WAIVE TO THE FULL EXTENT PERMITTED BY LAW ANY OBJECTION THAT THEY MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH
LITIGATION, PROCEEDING OR ACTION IN ANY SUCH COURT OR THAT ANY SUCH LITIGATION, PROCEEDING OR ACTION WAS BROUGHT IN AN INCONVENIENT
FORUM.

 

    	18

    	 

    

 

9.5.2   EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT
ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG
OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.5.

 

9.6             Notices.

 

9.6.1   Notice
Requirements. Any notice, request, demand, waiver, consent, approval, or other communication permitted or required under this
Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if (i) delivered by hand
or sent by email to the email addresses to be specified by each Party within sixty (60) days hereof, (ii) by internationally recognized
overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified
in Section 9.6.2 or (iii) to such other address as the Party to whom notice is to be given may have provided to the other
Party in accordance with this Section 9.6.1. Such Notice shall be deemed to have been given as of the date delivered by
hand or transmitted by email or on the second Business Day (at the place of delivery) after deposit with an internationally recognized
overnight delivery service. Any notice delivered by email shall be confirmed by a hard copy delivered as soon as practicable thereafter.
This Section 9.6.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing
their obligations under the terms of this Agreement.

 

    	19

    	 

    

 

9.6.2   Address
for Notice.

 

If
to ALNE, to:

 

Unique
Growing Solutions, Inc.

100
Europa Drive

Chapel
Hill, NC 27517

Attention:
Chief Executive Officer

 

with
a copy (which shall not constitute notice) to:

 

Szaferman,
Lakind, Blumstein & Blader, P.C.

101
Grovers Mill Road, Suite 200

Lawrenceville,
NJ

Attention:
Gregg E. Jaclin

 

If
to Lamina, to:

 

Lamina
Equities Corp.

1901
Fort Myer Drive

Suite
800

Arlington,
VA 22209

Attention:
Chief Executive Officer

 

with
a copy (which shall not constitute notice) to:

 

Stradley
Ronon Stevens & Young, LLP

1250
Connecticut Avenue, N.W., Suite 500

Washington,
DC 20036-2652

Attention:
Thomas L. Hanley

 

9.7             Entire
Agreement; Amendments. This Agreement sets forth and constitutes the entire agreement and understanding between the
Parties with respect to the subject matter hereof and all prior agreements, understandings, promises, and representations, whether
written or oral, with respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations
or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release, or discharge
shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties.

 

9.8             Waiver
and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that
is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed
by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the
failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other
breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative
and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.

 

    	20

    	 

    

 

9.9             No
Benefit to Third Parties. Covenants and agreements set forth in this Agreement are for the sole benefit of the Parties
hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons.

 

9.10           Further
Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments
and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and
instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out
more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies
under this Agreement.

 

9.11           Relationship
of the Parties. It is expressly agreed that Lamina, on the one hand, and ALNE, on the other hand, shall be independent
contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture, or agency. Neither
Lamina, on the one hand, nor ALNE, on the other hand, shall have the authority to make any statements, representations, or commitments
of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party
to do so. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations
incurred by reason of any such employment shall be for the account and expense of such Party.

 

9.12           Counterparts.
This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. This Agreement may be executed by electronically transmitted signatures and such
signatures shall be deemed to bind each Party hereto as if they were original signatures.

 

9.13           References.
Unless otherwise specified, (i) references in this Agreement to any Article or Section shall mean references to such Article
or Section of this Agreement, (ii) references in any Section to any clause are references to such clause of such Section,
and (iii) references to any agreement, instrument, or other document in this Agreement refer to such agreement, instrument,
or other document as originally executed or, if subsequently amended, replaced, or supplemented from time to time, as so amended,
replaced, or supplemented and in effect at the relevant time of reference thereto.

 

9.14           Construction.
Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the
use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever
this Agreement refers to a number of days, unless otherwise specified, such number refers to days. The captions of this Agreement
are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or
the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes”
as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this
Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied
against either Party hereto. Each Party represents that it has been represented by legal counsel in connection with this Agreement
and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this
Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	21

    	 

    

 

THIS AGREEMENT
IS EXECUTED by the authorized representatives of the Parties as of the Effective Date.

 

	LAMINA
    EQUITIES CORPORATION	UNIQUE
    GROWING SOLUTIONS, INC.
	 	(F/K/A ALTERNATIVE
    ENERGY & ENVIRONMENTAL SOLUTIONS, INC.)

 

	By:	/s/
    Raouf Albert Guirguis	 	By:	/s/
    Peter Coker
	Name:	Raouf
    Albert Guirguis	 	Name:	Peter
    Coker
	Title:	Chairman
    and CEO	 	Title:	President

 

 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]